AU6405596A - Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis - Google Patents
Use of stat 5 sh2 domain specific compounds to enhance erythropoiesisInfo
- Publication number
- AU6405596A AU6405596A AU64055/96A AU6405596A AU6405596A AU 6405596 A AU6405596 A AU 6405596A AU 64055/96 A AU64055/96 A AU 64055/96A AU 6405596 A AU6405596 A AU 6405596A AU 6405596 A AU6405596 A AU 6405596A
- Authority
- AU
- Australia
- Prior art keywords
- stat
- specific compounds
- domain specific
- enhance erythropoiesis
- erythropoiesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49735795A | 1995-06-30 | 1995-06-30 | |
US497357 | 1995-06-30 | ||
US59871596A | 1996-02-08 | 1996-02-08 | |
US598715 | 1996-02-08 | ||
PCT/US1996/011158 WO1997002024A1 (fr) | 1995-06-30 | 1996-06-28 | Utilisation de composes se liant specifiquement au domaine stat 5 sh2 pour augmenter l'erythropoiese |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6405596A true AU6405596A (en) | 1997-02-05 |
Family
ID=27052471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU64055/96A Abandoned AU6405596A (en) | 1995-06-30 | 1996-06-28 | Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0835104A4 (fr) |
JP (1) | JPH10512585A (fr) |
AU (1) | AU6405596A (fr) |
CA (1) | CA2225666A1 (fr) |
WO (1) | WO1997002024A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4440596A (en) * | 1995-02-10 | 1996-08-22 | Smithkline Beecham Corporation | Use of hcp SH2 specific compounds to enhance erythropoiesis |
DE19929787A1 (de) * | 1999-06-29 | 2001-01-04 | Bayer Ag | Neue 4-(2-Oxodihydrooxadiazinylphenyl)amide und ihre Verwendung |
ATE524441T1 (de) | 2000-12-28 | 2011-09-15 | Daiichi Seiyaku Co | Vla-4-inhibitoren |
CN100469769C (zh) | 2003-03-24 | 2009-03-18 | 弗·哈夫曼-拉罗切有限公司 | 作为逆转录酶抑制剂的苄基-哒嗪酮 |
US7691894B2 (en) | 2003-07-24 | 2010-04-06 | Daiichi Pharmaceutical Co., Ltd. | Cyclohexanecarboxylic acid compound |
CA2559552A1 (fr) | 2004-03-23 | 2005-09-29 | F. Hoffmann-La Roche Ag | Derives benzyl-pyridazinone servant d'inhibiteurs d'une transcriptase inverse non nucleosidique |
WO2007039463A1 (fr) | 2005-09-30 | 2007-04-12 | F. Hoffmann-La Roche Ag | Inhibiteurs non nucléosidiques de transcriptase inverse |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4482571A (en) * | 1982-06-21 | 1984-11-13 | University Of Pittsburgh | Sickle cell anemia treatment and compound |
US4745099A (en) * | 1985-02-06 | 1988-05-17 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of malignant tumors |
US4987121A (en) * | 1988-05-27 | 1991-01-22 | Center For Innovative Technology | Erythropoietic factor |
CA2054602C (fr) * | 1991-10-31 | 2003-04-22 | Anthony Pawson | Methode de dosage d'une substance influant sur un systeme de regulation d'un ligand phosphoryle-sh2 |
AU5136093A (en) * | 1992-09-25 | 1994-04-26 | Warner-Lambert Company | Peptide antagonists of sh2 binding and therapeutic uses thereof |
US5366996A (en) * | 1992-12-07 | 1994-11-22 | Elford Howard L | Method of treating hemoglobinopathies |
US5580979A (en) * | 1994-03-15 | 1996-12-03 | Trustees Of Tufts University | Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions |
AU4440596A (en) * | 1995-02-10 | 1996-08-22 | Smithkline Beecham Corporation | Use of hcp SH2 specific compounds to enhance erythropoiesis |
-
1996
- 1996-06-28 CA CA002225666A patent/CA2225666A1/fr not_active Abandoned
- 1996-06-28 AU AU64055/96A patent/AU6405596A/en not_active Abandoned
- 1996-06-28 WO PCT/US1996/011158 patent/WO1997002024A1/fr not_active Application Discontinuation
- 1996-06-28 EP EP96923579A patent/EP0835104A4/fr not_active Withdrawn
- 1996-06-28 JP JP9505268A patent/JPH10512585A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0835104A1 (fr) | 1998-04-15 |
CA2225666A1 (fr) | 1997-01-23 |
WO1997002024A1 (fr) | 1997-01-23 |
JPH10512585A (ja) | 1998-12-02 |
EP0835104A4 (fr) | 1999-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU6103496A (en) | Stable hydroalcoholic compositions | |
EP0694552A3 (fr) | Préparation des composés organosiliciques contenant de soufre | |
AU3299195A (en) | Inhibition of helicobacter | |
AU7482396A (en) | Substituted aryl pyrroles, compositions containing such compounds and methods of use | |
AU7002894A (en) | Measurement of water content | |
AU2872795A (en) | Inhibition of platelet binding | |
AU4680797A (en) | Preparation of substituted guanidines | |
AU4329396A (en) | Use of 3,4-diphenylchromans | |
AU7392696A (en) | Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins | |
AU6759596A (en) | Compensation of dispersion | |
GB9508791D0 (en) | Compositions of matter | |
AU7529096A (en) | Substituted aryl pyrroles, compositions containing such compounds and methods of use | |
AU7638391A (en) | Derivatives of 3'- and 3"-0-desmethylavermectin compounds | |
AU5237296A (en) | Use of pyrrole compounds as antifouling agents | |
AU6480796A (en) | Use of stat 6 sh2 domain specific compounds to treat allergic reactions | |
AU6405596A (en) | Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis | |
AU6768190A (en) | Preparation of flakes | |
AU4224096A (en) | Use of phenylcyclohexylcarboxamides | |
AU4440596A (en) | Use of hcp SH2 specific compounds to enhance erythropoiesis | |
GB9507297D0 (en) | New composition of matter | |
AU3724593A (en) | Polyfluoroalkylation of aromatic compounds | |
PL310675A1 (en) | Application of ferrocene | |
AU3948395A (en) | Synthesis of 6-azaandrostenones | |
AU1870295A (en) | Novel derivatives of tetramethylcyclopropane | |
ZA965499B (en) | Use of Stat 5 SH2 domain specific compounds to enhance erythropoiesis. |